2026Q1 HIMS Earnings Release Hims & Hers Conference Call1 CEO Remarks(Script)

Thanks, Bill. Good afternoon, everyone, and thank you for joining us. It's been a strong, meaningful start to the year at Hims and Hers. We've made significant progress on the strategic objectives that we believe will define our platform for the next decade. Importantly, 2026 is proving to be a year of accelerating growth, which reinforces our confidence in our ambitious 2030 targets. Before YMI takes us through our results, I want to highlight a few key areas that underscore our progress. First, our US business is positioned to accelerate as we introduce new specialties and shift our weight loss strategy toward a globally unified approach. Second, our global scale is quickly becoming a competitive advantage, not only because it expands our TAM, but because it expands our value to industry partners and strengthens the network effects of our platform. Third, we are deepening our customer relationships while filling real painful gaps in the traditional care system with a more proactive care offering. This means we are creating the opportunity for longer-term relationships with our customers. Fourth, continued investment in our data and technology infrastructure is building an increasingly agile platform that gets smarter with every new customer. With tens of millions of customer touch points annually and a closed loop provider network, we're massing a powerful data set that is becoming harder to replicate. These investments are enabling faster, more efficient geographic and product expansion, more valuable customer interactions and deeper platform engagement. With that foundation, Hims and Hers is on its way to becoming an everyday health partner, not just for the nearly 2.66 million people we currently serve, but for millions more around the world. Let's start with the building momentum we're seeing in the US. The breadth of care we can provide is becoming a real strategic advantage, giving customers more ways to start with Hims and Hers and more reasons to stay with us over time. We've seen momentum in newer specialties like testosterone, menopause, and labs, and our expanding selection of branded GLP-1 solutions is driving accelerating momentum in our weight loss business. The number of people we can help has never been larger or more diverse, and we're working to ensure they have access to the broadest array of treatment options possible. In weight alone, more than 100 million adults in the US are struggling. Demand for effective accessible treatments is increasing and the market is evolving rapidly to meet this need with more form factors and lower prices. In March, we announced a strategic shift in our weight loss business that recognizes this evolution and focuses on providing customers on our platform with access to the broadest possible assortment of innovative medications alongside a comprehensive experience. That includes access to the data-driven clinical care and lifestyle support our customers have come to expect. Platforms like ours are the place pharma, biotech, and diagnostic companies are increasingly relying on to reach more people with innovative treatments and services. For example, our collaboration with Novo Nordisk shows what's possible when health innovators work together to help more people feel great. We are seeing adoption in weight loss near record levels, even beyond the demand we saw following this year's New Year's and Super Bowl campaigns. Within 6 weeks of introducing direct access to Novo Nordisk's GLP-1 products to our platform, we have fulfilled more than 125,000 shipments for weight loss products. Our customers are excited about the Wegovy pill in particular. We've seen them respond extremely well to the affordable price point, impressive efficacy and strong safety profile. It's clearly a strong combination of efficacy, safety, and affordability. Novo has been a terrific partner for us, and I'm excited to explore further ways we might collaborate in the future. Last month, we also announced that providers on our platform can now send prescriptions for Zepbound vials and Quick Pen, as well as Sando to the Lilly Direct Pharmacy and access self-pay pricing for Hims and Hers customers. Our ability to drive awareness and cultural conversations about accessibility as well as our investment in a deeply personal continuous experience gives our partners confidence that the people we are helping them reach are getting access to great care and are more likely to remain engaged over time. Moving to the second area driving our progress: growing global scale. We are rapidly becoming the world's largest consumer health platform, which multiplies our impact. We expect our planned acquisition of Eucalyptus to close in the second half of this year. This will extend our leadership position in consumer health across Australia, the UK, Germany, Japan, and Canada by leveraging local expertise and existing industry relationships. As we strengthen our presence in current and new regions, we have the opportunity to impact hundreds of millions of people, bringing more data points into our ecosystem and extending the network effects of our platform globally. But bringing customers to the platform is only the first step. We're helping customers build a long-term daily health routine that they're motivated to maintain, turning better access and expanded treatment options into better health and building relationships that we believe can last for decades. We see ourselves as the best global platform for our industry partners for two reasons. First, our global presence allows us to drive category growth in new and existing markets. Second, by providing a high-touch personalized experience, our platform is designed to help customers stick to their treatment plans longer and better achieve their goals than with medication alone. That leads me to the third area of progress I want to highlight. As we grow, we are becoming more than just a destination for anyone looking to manage existing conditions. We are a trusted comprehensive health partner that's helping customers proactively discover early signs of conditions that may not be symptomatic yet. The strength of our testosterone offering, which is now serving tens of thousands of men, is the perfect demonstration of this. For most men, signs of low testosterone can be overlooked as just being tired or part of getting older. Through Hims, that changes. We've designed the offering to catch an important issue most men can't see before it becomes difficult to ignore. Customers can track their testosterone levels over time through simple at-home blood tests and work with the providers to determine what treatment is right for them and then easily adjust that treatment if appropriate based on their latest blood test. We're seeing this kind of proactive relationship and seamless at-home experience drive real results for customers. 95% of Hims customers relying on us for this testosterone support saw an increase in testosterone levels within two months. By prioritizing investments that deepen our customer relationships, we're making it simpler for anyone to be more proactive about feeling their best. We believe our investment in YourBio's micro needle blood sampling technology will make deeper health insights across key biomarkers even easier to access with a simple painless blood draw. Instead of waiting for symptoms like cardiovascular risk, sexual dysfunction, or hormone imbalance to appear, customers can get a full picture of their current health and manage certain risk factors before they turn into conditions that impact their daily life. That information layer will be key in supporting new specialties like testosterone and menopause as they scale. But more importantly, it allows our platform to evolve with our customers as their needs change. More and more we see customers looking for truly proactive and continuous care informed by health insights that help them not just get healthy but stay healthy. This is foundational to how the Hims and Hers customer experience improves over time. This brings me to the fourth area of progress I want to highlight. We are building a health platform that delivers access to higher quality care as we expand and that is becoming harder to replicate. I'd like to invite Mo El Shinawi, our CTO, to share more on the progress his team has made and the customer experience they're bringing to life. Given how quickly our technology infrastructure is expanding and the immense impact we expect it to have on the future of the business, we are excited to have Mo join us. All of the work in this area won't just power deeper insights and stronger relationships in our current categories. We believe it will also underpin our ability to enter emerging categories like peptides with a clinically rigorous, information-rich intake process that is designed to keep customers safe and providers well informed. Our medical team sees meaningful potential in several peptide therapies and we are pleased to see the FDA moving to more clearly define what is safe and allowable here. The standard bearers in this new category will be the companies that keep the experience physician-first, transparent, and focused on successful customer outcomes. That doesn't exist in today's gray market where the only peptide options are unregulated, inconsistent in quality, and rarely include clinical support. Our approach to this category would be different with a focus on physician insights and oversight, a commitment to advancing clinical learnings about safety and efficacy, and access to high-quality treatments. We believe our verticalized infrastructure and domestic supply chain, which we strengthened by investing in our own US-based peptide facility last year, means that our customers can trust us to bring the same rigorous approach to peptide therapies that they've seen in other categories. Said more simply, we won't launch access to peptides until we meet these very high standards that we believe everyone should be meeting. I'll end by saying that I have never been more confident that we are building the future of health. 9 years of data, a verticalized domestic supply chain, an agile and intelligent platform, a leading global footprint, and a growing network of trusted health innovators gives us distinct advantages and reinforces our confidence in our 2030 targets of at least 6.5 billion in revenue and 1.3 billion in adjusted EBITDA. We are redefining how the world accesses care, becoming the global destination people trust to feel their best every day. On our platform, customers discover a holistic data-driven experience built for their actual lives, not a generic system. We are changing what people believe is possible. Health that is simple, deeply personal, and built for everyday life. I'll now pass to YMI.